Coloplast A/S

XTRA:CBHD Stock Report

Market Cap: €25.0b

Coloplast Valuation

Is CBHD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBHD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€161.48
Fair Value
31.0% undervalued intrinsic discount
22
Number of Analysts

Below Fair Value: CBHD (€111.35) is trading below our estimate of fair value (€161.48)

Significantly Below Fair Value: CBHD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBHD?

Key metric: As CBHD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CBHD. This is calculated by dividing CBHD's market cap by their current earnings.
What is CBHD's PE Ratio?
PE Ratio37x
EarningsDKK 5.05b
Market CapDKK 186.86b

Price to Earnings Ratio vs Peers

How does CBHD's PE Ratio compare to its peers?

The above table shows the PE ratio for CBHD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.8x
PHH2 Paul Hartmann
13.3xn/a€788.5m
SHL Siemens Healthineers
31.7x13.8%€61.5b
FME Fresenius Medical Care
21.4x16.8%€14.1b
AFX Carl Zeiss Meditec
28.9x15.2%€5.2b
CBHD Coloplast
37x11.9%€186.9b

Price-To-Earnings vs Peers: CBHD is expensive based on its Price-To-Earnings Ratio (37x) compared to the peer average (23.8x).

Price to Earnings Ratio vs Industry

How does CBHD's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CBHD 37.0xIndustry Avg. 32.1xNo. of Companies7PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CBHD is expensive based on its Price-To-Earnings Ratio (37x) compared to the European Medical Equipment industry average (32.1x).

Price to Earnings Ratio vs Fair Ratio

What is CBHD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBHD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37x
Fair PE Ratio36.7x

Price-To-Earnings vs Fair Ratio: CBHD is expensive based on its Price-To-Earnings Ratio (37x) compared to the estimated Fair Price-To-Earnings Ratio (36.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CBHD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€121.19
0%
11.2%€138.06€93.83n/a22
Jan ’26n/a
€123.92
0%
9.4%€138.07€93.84n/a21
Dec ’25n/a
€123.94
0%
9.4%€138.06€93.82n/a21
Nov ’25n/a
€122.49
0%
11.0%€140.82€93.88n/a21
Oct ’25n/a
€122.54
0%
11.0%€142.18€93.89n/a20
Sep ’25n/a
€122.17
0%
11.3%€142.09€93.84n/a20
Aug ’25n/a
€121.42
0%
11.0%€142.07€95.16n/a20
Jul ’25n/a
€120.02
0%
10.5%€142.08€95.17n/a20
Jun ’25n/a
€121.95
0%
10.2%€142.06€95.16n/a19
May ’25n/a
€122.93
0%
10.9%€142.09€93.83n/a19
Apr ’25n/a
€120.32
0%
10.3%€142.13€93.86n/a19
Mar ’25n/a
€116.96
0%
10.1%€134.16€93.91n/a19
Feb ’25n/a
€110.46
0%
9.8%€129.01€84.62n/a19
Jan ’25n/a
€109.56
0%
10.3%€129.07€84.66n/a18
Dec ’24n/a
€109.69
0%
10.1%€129.05€84.65n/a18
Nov ’24n/a
€113.71
0%
9.2%€131.29€91.90n/a18
Oct ’24n/a
€116.05
0%
9.9%€134.12€92.01n/a17
Sep ’24n/a
€121.79
0%
10.1%€143.59€96.62n/a15
Aug ’24n/a
€124.66
0%
9.9%€143.60€96.63n/a16
Jul ’24n/a
€122.90
0%
11.0%€143.65€92.63n/a16
Jun ’24n/a
€122.95
0%
11.0%€143.71€92.67n/a16
May ’24n/a
€122.53
0%
10.0%€140.25€92.61n/a16
Apr ’24n/a
€121.15
0%
9.8%€140.26€92.61n/a16
Mar ’24n/a
€121.26
0%
10.2%€140.31€92.64n/a15
Feb ’24n/a
€121.99
0%
9.7%€140.50€92.77n/a15
Analyst Price Target
Consensus Narrative from 22 Analysts
€121.29
Fair Value
8.2% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 23:29
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 48 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Robert BateBarclays
Hassan Al-WakeelBarclays